

10th Antibody Drug & Novel Biological Summit 2020

Feb.21 Anternoon Antibody drugs industrialization – from 1 to 10

Chairman : Ning LI , CEO , Shanghai Junshi Biosciences Co., Ltd. ; Gang WANG , CQO , Shanghai Junshi Biosciences Co., Ltd.

CO-HOST : Shanghai Junshi Biosciences Co., Ltd.

13:30-14:15	Panel Discussion : Recall the past 10 years, Anticipate the next 10 years Panelist : Ning LI , CEO , Junshi Biosciences ; Chris CHEN , CEO , WuXi Biologics; Scott LIU , CEO , Henlius
14:15-14:45	“Explore the challenges and marketing prospects of large scale manufacturing”
14:45-15:15	“How does the experiment of on-site inspection change into instruction of project implementation?”
15:15-15:45	“How to balance the cost and quality in industrial production of biological drug” Scott LIU , CEO , Henlius
15:45-16:05	“Rapid process development and production under quality assurance” UP-BIOTECH
16:05-16:35	“ The future of biopharmaceutical commercial production- Continuous production” Xun LIU, Deputy General Manager, Jiangsu Hengrui Medicine

Feb.22 Morning Innovative Drug Discovery – from 0 to 1

Chairman : Lianshan ZHANG, PhD Senior Vice President and Global R&D President, Jiangsu Hengrui Medicine ; Hua YING , Executive Director , Shanghai Hengrui Medicine

CO-HOST : Jiangsu Hengrui Medicine

08:30-08:40	“Rise to the challenges and chances, mapping the development strategy of antibody drug” Lianshan ZHANG, PhD Senior Vice President and Global R&D President, Jiangsu Hengrui Medicine
08:40-09:10	“ How to establish global R & D pipeline?”
09:10-09:40	“Biology Drives Selection of Targets and Design of Antibodies as Innovative Therapeutics” Jijie GU, CSO, Wuxi Biologics
09:40-10:10	“Target discovery and application of FOXP3 + Treg functional stability “

	Bin LI, Vice Director, Shanghai Institute of Immunology
10:10-10:30	“Application of Expi protein expression system in the development of antibody drugs” Thermo Fisher
10:30-11:00	Topic to be determined Zichun HUA, Nanjing University
11:00-11:30	Developing breakthrough therapies as bispecific antibodies Chenbing WU, CEO, EpimAb
Feb.22 Afternoon Drug Development Strategy – from 0 to 1 Chairman : Yuling LI, CEO, Innoforce Pharmaceuticals Co., Ltd. CO-HOST : Innoforce Pharmaceuticals Co., Ltd.	
13:30-14:15	Panel Discussion : Development and exploration of global biological drug Panelist : Jianwei ZHU, Dean, Shanghai Jiao Tong University
14:15-14:45	“The indispensable segments and indicators of assessing and selecting the Innovative biopharmaceutical candidates - the adaption of commercial products and scale production” Jerry YANG, VP, Transcenta
14:45-15:15	“Patient-centered development of clinical indications : nich indication for fast approval”
15:15-15:35	“CMC development strategy in clinical stage” Weifeng ZHANG, VP, GenScript
15:35-16:05	“Therapy development of optimal combination antibody drugs: strategy and solution design”
16:05-16:35	“Key and difficulties in bispecific antibody development”
Feb.21 Afternoon New Prospect – Commercialization	
14:00-14:30	“Policy of medical insurance help biological drug to reach patients”

14:30-15:30	Panel Discussion : Commercialization of biological drugs: chances and challenges in China 1、 Self-built sales team or selecting CSO 2、 How far is “4+7”from biopharmaceutical industry? 3、 How to make up product pipeline?
15:30-17:00	Road Show : CSO Road Show (15mins per company , total 6 companies , opportunity opening...)
Feb. Afternoon R&D – Small Molecule Target Chairman : Bin SHI,CSO, TYK Medicines CO-HOST : SAPA-China	
13:30-13:50	“Cross-border cooperation business model and the latest cooperation progress between China and the United States” Fei JIANG,VP, Sinopharm Capital
13:50-14:30	“New drug targets in tumor immunity and opportunities for small molecule drug development” Yuli XIE,CEO, Suzhou Autopharm
14:30-15:10	“Clinical research and treatment of NASH” Jiangao FAN, Director of Gastroenterology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine
15:10-15:30	Opportunity Opening
15:30-16:15	Panel Discussion : Opportunities and challenges in the development of anti-tumor small molecule drugs Panelist : Yusheng WU, Chairman, TYK Medicines; Min Li, VP, Zhejiang Huahai Pharmaceutical Co., Ltd.; Mingde XIA, Senior Director of WWDA, Johnson & Johnson Global External Innovation; Yuli XIE,CEO, Suzhou Autopharm
6:15-17:00	Panel : Research Status of NASH Drug Targets Moderator : Weikang Tao, Deputy General Manager, Jiangsu Hengrui Medicine Panelist : Liping LIU, Chairman, HighTide Therapeutics; Binhua LYU, VP, Suzhou Zelgen Biopharmaceuticals Co., Ltd.; Yuntao WAN, VP, Shijiazhuang Pharmaceutical Group Co., Ltd. ; Bin SHI,CSO, TYK Medicines; Jiangao FAN, Director of Gastroenterology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

Sixth Immunotherapy Industry Summit 2020

Afternoon on 21th February Discussion on R&D and Strategy

Chairman: Lin Yang, CEO, PersonGene; Yarong Liu,

13:30-14:00	keynote Speech: the Newest development and the trend of CAR-T Cell
14:00-14:30	keynote Speech: the Chance and Challenge of NK Cell Immunotherapy Speaker: Weihua Xiao, Deputy Director of Pharmaceutical Biotechnology Department , School of Life Sciences, University of Science and Technology of China
14:30-14:50	How does CDMO make the industrial promotion for Cell Immunotherapy?
14:50-15:20	keynote Speech: The battle between TCR-T, Blood Tumor and Solid Tumor Speaker: Liangping Li, Professor, Jinan University Faculty of Medical Science
15:20-15:50	keynote Speech: The development of the Tumors on TCR-T Cell Immunotherapy Speaker: Lietao Li, CEO , Lion TCR
15:50-16:20	keynote Speech : Next Generation CAR T Cells (Tough-CAR) for the Immunotherapy of T Cell Malignancies Speaker: Lin Yang, President, PersonGene
16:20-17:05	Panel Discussion: Strategies on the Tumor Cell Immunotherapy Development

Morning on 22nd February The establishment of the system on the equipment and quality development of CAR-T

Chairman: Jennifer Wang , Senior Director, JW Therapeutics

08:30-09:00	keynote Speech: CMC requirements on Cell Immunotherapy Speaker: Kai Gao, ;Former head of Antibody evaluation department of CDE ;Professor; Shanghai University
-------------	---

09:00-09:30	Keynote Speech Speech: Establish the quality system considering the Risk control Speaker: Jennifer Wang , Senior Director, JW Therapeutics
09:30-09:50	keynote Speech: the Strategy on the carrier ecological development of the Gene Cell Therapy Speaker: Shigagn Wei; Director of the Plasmid virus technology department ;GenScript Biotech Corporation
09:50-10:20	Keynote Speech Speech: the Development, Quality Control Research and Test on Yescarta Speaker: Tongjing Tao, Quality Cotroller , Fosun Kite Biotechnology Co., Ltd
10:50-11:20	Keynote Speech Speech: the Challenge on the technology development and methodological validation of CAR-T Speaker: Xinpo Jiang, Senior Director, Nanjing Legend Pharmaceutical & Chemical Co., Ltd
Afternoon on 22nd February The Explore of the Immunotherapy Industrial Development	
13:30-14:15	Panel Discussion: Analysis Chinese Industrial Model on the base of the Global Products on public
14:15-14:45	Keynote Speech: The main point explains on the approve and compliance of Car-T therapy Industrial development Speaker: Jing Han, Doctor, Former head of Antibody evaluation department
14:45-15:15	Keynote Speech: the key points on the Manufacturing and Designing of Car-T Products
15:15-15:35	Keynote Speech: The application on the Cell Therapy of Clouds Magnetic beads screening and RNA scope. Speaker: Changping Ma, Technical application Experts , AntixBiotechCo.,Ltd.
15:35-16:05	Keynote Speech Speech: the Whole Chain of the Individualized therapy
Afternoon on 21th February The release on the clinical research of the creative drugs	
Chairman: Jianfeng Zhou,Wuhan ; Director of hematology ;Tongji Hospital	
13:30-13:50	Keynote Speech: the clinical development of the CD19-CART humanization Cell Treatment Relapse and Malignant hematologic neoplasms Speaker: Huimin Meng,Doctor, PersonGene
13:50-14:10	Keynote Speech: the Summary on CAR-T treatment of B. Recurrence after emergency allogeneic transplantation and Maintenance

	treatment Speaker: Qi Deng, Director of hematology, Tianjin First Central Hospital	
14:10-14:30	Keynote Speech: the clinical research on the IM19 for recurrent refractory non-hodgkin's lymphoma Speaker: Yuqin Song, Professor, Beijing Cancer Hospital Dean Assistant Enterprise: Beijing Immunochina Pharmaceuticals Co., Ltd.	
14:30-14:50	Keynote Speech : How to provide the solutions on the cell treatment and CAR-T with double track systems Enterprise: Thermo Fisher Scientific	
14:30-14:50	Keynote Speech: the density of CAR surface Cell will effect CD19; the clinical result and bad reflection on CAR-T Speaker: Jianqiang Li, Doctor, Hebei Senlang Biotechnology Co., Ltd	
15:10-15:30	Keynote Speech: Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptors (CAR)-T in relapsed/refractory acute lymphoblastic leukemia Speaker: Zhi Yang, Doctor, Precision Biotech	
15:30-15:50	Keynote Speech: Clinical Responses and Pharmacokinetics of Fully Human BCMA Targeting CAR T Cell Therapy in R/R Multiple Myeloma Speaker: Guang Hu, Doctor, IASO BIO	
15:50-17:30	Unsettled keynote Speech: Gracell, Wuhan Bio-Raid Biotechnology Co.,Ltd.	
Evening on 21th February Round Table Meeting (Invited to join) Moderator : Jianfeng Zhou,Wuhan ; Director of hematology ;Tongji Hospital		
19:00-21:00	1.The considering points on Chinese Cell Therapy Industrial Development	Confirmed Guests : Jianfeng Zhou,Wuhan ,Director of hematology ,Tongji Hospital; Kai Gao,Former head of Antibody evaluation department of CDE ,Professor,Shanghai University; Jijun Yuan,CEO , GENE; Lin Yang, CEO, PersonGene ; Wei Cao,CEO, Gracell; Ting He,CEO, Beijing Immunochina Pharmaceuticals Co., Ltd.;Yiping Li, CEO, JW Therapeutics; Liqun Wang ,CEO, Fosun Kite Biotechnology Co., Ltd; Cheng Qian, CEO, Precision Biotech; Qiushi Li ,COO, Cure Genetics ;Bizuo Liu,

	<p>(How to promote, Tips and the existence with the system matured)</p> <p>The executive of the Immunotherapy of Cell CMC with the industrial development</p> <p>2.The discussion on the ethical during the Cell Research and Development</p>	<p>CEO, Cellular Biomedicine Group; Ping Sun, CEO, Metanotitia Inc.; Tongcun Zhang ,CEO, Bio-Raid; Yarong Liu; Jinhua Zhang, CEO, IASO BIO; Shengmin Guo ,CEO, Hebei Senlang Biotechnology Co., Ltd; Xiangjun Zhou, Chief scientist, HRYZ BIO TECH CO.; Lanlin Wu, CEO, Dendreon.</p>
--	--	---

8th MOLECULAR DIAGNOSTICS SUMMIT

21st February P.M

Molecular diagnosis market pattern and enterprise strategy

14:00-14:30	keynote Speech “Distribution of molecular diagnostic product line and promotion of market strategy in China“
14:30-15:00	keynote Speech “Industrialization road of non-invasive production screen: past, present and future“
15:30-16:00	keynote Speech “Pipeline construction and clinical application promotion of tumor products in the next 3-5 years“ Speaker : Yang SHAO , CEO , Geneseeq Technology Inc.
16:00-16:30	keynote Speech “Clinical infection diagnosis products based on NGS Technology “
16:30-17:00	keynote Speech “Development and marketing experience of clinical molecular diagnosis products“

17:00-17:30	Panel discussion: "How to build competitive molecular diagnostic products? "
22nd February A.M Multi platform detection technology for clinical diagnosis	
Chairman: Qiang Zhao, Medical director ,Guangzhou KingMed Diagnostics Group Co., Ltd.	
08:30-09:00	keynote Speech "The past, present and future of CMA Technology" Speaker : Qiang ZHAO, Medical director ,Guangzhou KingMed Diagnostics Group Co., Ltd.
09:00-09:30	keynote Speech "Current situation, problems and solutions of NGS Technology" Speaker : Daixing ZHOU, CEO, BerryGenomics
09:30-09:50	keynote Speech "The solution and application of digital PCR" Speaker : Rain Sure Bio
09:50-10:20	keynote Speech "Clinical application prospect of mass spectrometry" Speaker : Technical Expert
10:20-10:40	keynote Speech "Research Progress of NTRK and Development of Diagnostic Products " Speaker : Thermo Fisher
10:40-11:10	keynote Speech "Application of multi platform and multi group technology in the field of molecular diagnosis" Speaker : Yongguo YU ,PHD, Xinhua Hospital Affiliated to Shanghai Jiaotong University school of medicine,
11:10-11:30	Interactive sessions : Strategy of building multi technology platform in molecular diagnosis laboratory
22nd February P.M Build competitive molecular diagnostic products	
Moderator : Xiaohang TONG, Decheng Capital	
13:30-14:15	Panel discussion: The choice of subdivision track and the formulation of product strategy
14:15-14:45	keynote Speech "Research and development prospect of infectious molecular diagnostic products"
14:45-15:15	keynote Speech "Molecular diagnosis of cardiovascular diseases"
15:15-15:45	keynote Speech "Development of rapid blood glucose detection"
15:45-16:15	keynote Speech "A new generation of diagnostic technology based on CRISPR Technology"
16:15-16:45	keynote Speech "Progress in clinical application of CTC liquid biopsy"

16:45-17:15	keynote Speech “The latest development of single cell sequencing in tumor research“
21st February P.M New drug creation and precise treatment Focus on concomitant diagnosis	
James TANG, MD/VP,MEDx (Suzhou) Translational Medicine Co.,Ltd	
13:30-14:00	keynote Speech “Concomitant diagnostic markers and clinical trials of new drugs“ Speaker : Xuchao ZHANG ,PHD/Professor/ Director of Lung Cancer Research Institute, Guangdong Provincial People's Hospital
14:00-14:30	keynote Speech “Clinical application and practical experience sharing of PD-L1 IHC concomitant diagnosis“ Speaker : Lingchuan GUO, Professor/ Chairman , Affiliated Hospital of Suzhou University
14:30-15:00	keynote Speech “Transformation and application of biomarkers in new drug development“ Speaker : Weidong JIANG, PHD/CSO, Henlius
15:00-15:20	Speaking opportunities open
15:20-15:50	keynote Speech “Concomitant diagnosis and molecular pathology of tumor targeted therapy“ Speaker : Jim Lu , PHD/ CEO , GoPath Labs
15:50-16:20	keynote Speech “Tumor immunotherapy with diagnosis and cooperation of pharmaceutical enterprises“ Speaker : James TANG, MD/VP, MEDx (Suzhou) Translational Medicine Co.,Ltd
16:20-17:30	Panel discussion: Adjoint diagnosis--- How pharmaceutical companies cooperate with diagnostic enterprises for win-win results 1.Talking about the current situation from the case : International and Chinese successful cases of concomitant diagnosis 2.Does the accompanying diagnosis need to be arranged in advance, Importance and urgency 3.Advice to diagnostic companies : Do you have the conditions to develop the accompanying diagnosis business? 4.How to promote the clinical application of concomitant diagnosis in China? Moderator :Nick , ZHANG ,PHD/ Chairman/ CEO, MEDx (Suzhou) Translational Medicine Co.,Ltd

Interview guests: Xuchao ZHANG ,PHD/Professor/ Director of Lung Cancer Research Institute, Guangdong Provincial People's Hospital; Lingchuan GUO, Professor/ Chairman , Affiliated Hospital of Suzhou University; Weidong JIANG, PHD/CSO, Henlius; Jim Lu , PHD/ CEO , GoPath Labs;Jie HU , VP , First Capital Listed investment company

22nd February A.M

Clinical application and quality supervision of new products and technologies for molecular diagnosis(Invitation Only)

Moderator :Bin XU, Chairman, Jiangsu center for clinical laboratory

09:00-09:30	keynote Speech “The current situation and thinking of LDT mode“ Speaker : Hualiang ,Wang, Chairman , Shanghai center for clinical laboratory
09:30-10:00	keynote Speech “Quality standard and quality control of molecular diagnostic products“
10:00-10:30	Interactive sessions : Clinical application and quality supervision of new products and technologies for molecular

22nd February P.M Register | Diagnostic topics

Since the launch of MAH for medical devices, the pilot areas have greatly shortened the research and development process of innovative products for medical devices, and promoted the development of corresponding cro and cdmO industries.

Focusing on the MAH system and cdmO industry focused in the industry, the theme of this special session is to find out the current situation and foundation of industrial development and the development experience of developed regions at home and abroad based on the in-depth study of subdivision fields (such as gene sequencing), and on this basis, carry out industrial positioning and construction of industrial service system (such as medical device inspection and testing platform, subdivision field CMO platform, etc.), so as to formulate industrial development strategies for regions Slightly.

3rd 17talk Investment and Financing leaders forum

Afternoon on 21st February

Forward-looking Dialogue on Global and Chinese healthcare investment

14:00-14:30	Keynote Speech 1: Release of financing data for biomedical projects in 2019
-------------	---

14:30-15:15	Panel 1: Global landscape: Global healthcare investment trends in 2020 from the perspective of JPM
15:15-16:00	Panel 2: Excavating 2020 investment gold mine: Analysis of subdivision track
16:00-16:45	Topic: How can investors and entrepreneurs cooperate and win
Morning on 22nd February IPO for Innovative Enterprises	
09:00-09:30	Keynote Speech 1: Biotechnology companies listed data released in 2019
09:30-10:00	Keynote Speech 2: How can HKSE and STAR promote the leapfrog development of biomedical enterprises
10:00-10:30	Keynote Speech 3 : How to lay out the enterprise listing plan in advance
10:30-11:30	Panel discussion: Review of the history of listing: sharing the experience of many entrepreneurs
21st February Open Road Show	
11:00-13:00	Moderator: Dr. Steven Kan, Chief Technology Officer and Head of CMC, Genor Biopharma Co., Ltd. Speaker: Dr. Ju -GemPharmatech Co.,Ltd-R&D director deputy general manager

13:00-15:00	<p>New product release & high quality exhibitors roadshow</p> <p>Moderator: Min Wang-PersonGen</p> <p>Instant access to the latest product releases in the industry</p>
15:00-16:00	<p>Industrial Park Road Show</p> <p>Gather powerful policy resources for the entrepreneurship and development of biomedical enterprises, and provide one-stop service for the r&d and value-added services of biomedical enterprises</p>
15:20-16:10	<p>Panel discussion:[technology] Research and development team discovery, construction, training, innovation</p>
16:10-17:00	<p>Panel discussion:[marketing] Organizational change and innovation in the process of commercialization</p>
22nd February open road show	
9:00-11:00	<p>New Technology Road show</p> <p>Display the most advanced technology in the industry</p>
11:00-12:00	<p>Road Show with diagnostic service providers</p> <p>Keep up with the rapid development of the market, show the latest achievements of international and diagnostic technology, and boost the development of the industry</p>
12:30-13:30	<p>Panel discussion: Friends</p> <p>Moderator: Dr.Victor Shi-Adicon clinical laboratories,inc-CEO</p> <p>Part 1: The love-hate relationship between entrepreneurs and investors</p> <p>Part 2: From philosophy of life to poetry</p> <p>Speaker:Jon Wang;Guoliang Yu-Innoforce-CEO</p>

13:30-14:30	Employer brand roadshow Display enterprise brand, image, talent organization structure
14:30-16:00	Supply chain service provider roadshow Gather cold chain logistics suppliers at home and abroad to provide multi-dimensional solutions for integrated medical cold chain